JAZZ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Jazz Pharmaceuticals (JAZZ) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive analyst sentiment, and upcoming product launches provide a solid foundation for growth. Despite recent market price declines, the technical indicators remain bullish, and the long-term outlook is favorable.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200), a positive MACD histogram (2.676), and RSI_6 at 73.262, which is in the neutral zone. Key support and resistance levels are Pivot: 179.159, R1: 191.734, S1: 166.583, R2: 199.503, S2: 158.814. The stock is currently trading near resistance levels, indicating potential for upward movement.
Strong Q4 revenue growth of 10.09% YoY, with total revenue reaching $4.3 billion in
Positive analyst sentiment with multiple price target increases (e.g., BofA to $275, Deutsche Bank to $255).
Upcoming Ziihera gastroesophageal adenocarcinoma launch, which is expected to drive revenue.
New drug Modeyso generated $48 million in revenue within months of launch.
Acquisition of Chimerix adds $200 million in deferred tax assets, enhancing focus on rare diseases.
Recent market price decline of -3.99% in regular trading and -1.57% in pre-market.
Gross margin dropped slightly to 73.01%, down -0.76% YoY.
Options activity shows significant put interest, indicating some market concerns about downside risks.
Jazz Pharmaceuticals reported strong financials for Q4 2025, with revenue increasing by 10.09% YoY to $1.2 billion, net income up 6.45% YoY to $203.45 million, and EPS up 7.07% YoY to $3.33. However, gross margin slightly declined to 73.01%. The company projects 2026 revenue between $4.25 billion and $4.50 billion, driven by products like Epidiolex and Modeyso.
Analysts are overwhelmingly positive on JAZZ, with multiple firms raising price targets recently. BofA raised its target to $275, Deutsche Bank to $255, Morgan Stanley to $226, and Wells Fargo to $250. Analysts cite strong guidance, reduced Oxybate headwinds, and the potential success of Ziihera as key reasons for their optimism.
